These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33875521)

  • 21. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
    Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
    Solano de la Asunción C; Terol MJ; Saus A; Olea B; Giménez E; Albert E; López-Jiménez J; Andreu R; García D; Fox L; Remigia MJ; Amat P; Solano C; Navarro D
    Br J Haematol; 2021 Nov; 195(4):637-641. PubMed ID: 34402042
    [No Abstract]   [Full Text] [Related]  

  • 23. Ibrutinib treatment improves T cell number and function in CLL patients.
    Long M; Beckwith K; Do P; Mundy BL; Gordon A; Lehman AM; Maddocks KJ; Cheney C; Jones JA; Flynn JM; Andritsos LA; Awan F; Fraietta JA; June CH; Maus MV; Woyach JA; Caligiuri MA; Johnson AJ; Muthusamy N; Byrd JC
    J Clin Invest; 2017 Aug; 127(8):3052-3064. PubMed ID: 28714866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial.
    Spaner DE; Luo Y; Wang G; Gallagher J; Tsui H; Shi Y
    Cancer Med; 2021 Dec; 10(24):8789-8798. PubMed ID: 34791813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.
    Nishida T; Hudecek M; Kostic A; Bleakley M; Warren EH; Maloney D; Storb R; Riddell SR
    Clin Cancer Res; 2009 Jul; 15(14):4759-68. PubMed ID: 19567591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation.
    Kollgaard T; Petersen SL; Hadrup SR; Masmas TN; Seremet T; Andersen MH; Madsen HO; Vindeløv L; thor Straten P
    Leukemia; 2005 Dec; 19(12):2273-80. PubMed ID: 16304575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
    Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
    Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
    Bravaccini S; Martinelli G; Cerchione C
    Cell Transplant; 2020; 29():963689720950209. PubMed ID: 32907382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ibrutinib dose modifications in the management of CLL.
    Hardy-Abeloos C; Pinotti R; Gabrilove J
    J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
    Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
    JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia.
    Manukyan G; Turcsanyi P; Mikulkova Z; Gabcova G; Urbanova R; Gajdos P; Smotkova Kraiczova V; Zehnalova S; Papajik T; Kriegova E
    Leuk Res; 2018 Sep; 72():113-119. PubMed ID: 30149317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening and monitoring of the BTK
    Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
    Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
    Kondo K; Shaim H; Thompson PA; Burger JA; Keating M; Estrov Z; Harris D; Kim E; Ferrajoli A; Daher M; Basar R; Muftuoglu M; Imahashi N; Alsuliman A; Sobieski C; Gokdemir E; Wierda W; Jain N; Liu E; Shpall EJ; Rezvani K
    Leukemia; 2018 Apr; 32(4):960-970. PubMed ID: 28972595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia.
    Liu Y; Song Y; Yin Q
    Front Immunol; 2022; 13():962552. PubMed ID: 36059445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Fraietta JA; Beckwith KA; Patel PR; Ruella M; Zheng Z; Barrett DM; Lacey SF; Melenhorst JJ; McGettigan SE; Cook DR; Zhang C; Xu J; Do P; Hulitt J; Kudchodkar SB; Cogdill AP; Gill S; Porter DL; Woyach JA; Long M; Johnson AJ; Maddocks K; Muthusamy N; Levine BL; June CH; Byrd JC; Maus MV
    Blood; 2016 Mar; 127(9):1117-27. PubMed ID: 26813675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
    Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
    Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number.
    Podhorecka M; Goracy A; Szymczyk A; Kowal M; Ibanez B; Jankowska-Lecka O; Macheta A; Nowaczynska A; Drab-Urbanek E; Chocholska S; Jawniak D; Hus M
    Oncotarget; 2017 May; 8(21):34661-34669. PubMed ID: 28416773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
    Tinhofer I; Marschitz I; Kos M; Henn T; Egle A; Villunger A; Greil R
    Blood; 1998 Jun; 91(11):4273-81. PubMed ID: 9596676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.
    de Weerdt I; Hofland T; Lameris R; Endstra S; Jongejan A; Moerland PD; de Bruin RCG; Remmerswaal EBM; Ten Berge IJM; Liu N; van der Stelt M; Faber LM; Levin MD; Eldering E; Tonino SH; de Gruijl TD; van der Vliet HJ; Kater AP
    Blood; 2018 Nov; 132(21):2260-2272. PubMed ID: 30213872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.